Anthem Biosciences IPO GMP Hits 27%, Oversubscribed 800% On Day 3; Last Chance To Apply, Bid or Skip?

Today is the last day for investors to subscribe for the Anthem Biosciences IPO, which so far has gathered a lot of attention in the market. The R&D company, which is going for a mainboard issue, is turning heads as it's trading with an Rs. 156 premium in the grey market. The Anthem Biosciences IPO opened for subscription on Monday, July 14.

Anthem Biosciences IPO Subscription Status on Day 3

As per NSE data updated at 11:30 AM, Wednesday, the Anthem Biosciences IPO has been subscribed 8.31 times in total. Retail investors have shown healthy participation, subscribing 3.55 times, while the non-institutional investor segment surged with a strong 10.26 times subscription. However, the Qualified Institutional Buyer category lagged slightly at 5.22 times.

Anthem Biosciences IPO GMP Today

According to data from the Investorgain website, the Anthem Biosciences IPO GMP today is Rs. 156, as of July 16, 2025, 9:30 AM. This big GMP is expected to give 27.37% of listing gains to the investors to get the allotted shares. The price band is Rs. 570 for the upper limit, and the potential listing price as per the current IPO GMP could be Rs. 726 per share.

Anthem Biosciences IPO Details: Price Band, Issue Size, Key Dates

The Anthem Biosciences IPO is a mainboard issue worth Rs. 3,395 crore and entirely an offer for sale of 5.96 crore equity shares. The IPO price band is set at Rs. 540 to Rs. 570 per share. The company has already raised Rs. 1,016.02 crore from anchor investors, which includes top domestic and global institutions.

The allotment of shares is likely to be done on Thursday, July 17, and the listing of Anthem Biosciences shares on NSE and BSE is scheduled for next week on July 21st.

Should You Subscribe to Anthem Biosciences IPO?

Broking firm Nirmal Bang Securities has issued a "Subscribe" rating for the Anthem Biosciences IPO, stating the company's strong global footprint.

"Anthem Biosciences currently has ~16 projects in final stages, including 10 late-stage molecules, which positions it well for future revenue growth. The company's historical 81% success rate in commercialising late-stage drugs further boosts investor confidence. Although the IPO is priced at a 71x FY25 expected EPS, slightly below peers, we believe the company's solid financials and sustainable business model justify the premium valuation in the future," the report further stated.

About Anthem Biosciences Ltd.

Anthem Biosciences Limited was incorporated in 2006 and is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO). The company operates across the full drug development lifecycle, offering services from discovery to commercial manufacturing.

Its offerings include fermentation-based APIs, probiotics, enzymes, peptides, vitamin analogues, and biosimilars. The company serves a global clientele of innovative biotech startups and large pharmaceutical giants, as per company data.

Disclaimer: The information provided in this article is for general informational purposes only and does not constitute financial, investment, or credit advice. The views and recommendations mentioned are based on publicly available data and expert opinions at the time of writing. Neither the author nor GoodReturns endorses any specific product or financial decision. GoodReturns.in and its affiliates are not responsible for any loss or damage resulting from reliance on the information presented.